Investigation tests drug to activate immune system, help fight cancer

June 15, 2017
The cancer cells will be cultured within the six-well BioCell, featured above, created by BioServe Space Technologies. Credit: BioServe Space Technologies

On Earth, research into antibody-drug conjugates to treat cancer has been around a while. The research presents a problem, though, because Earth-based laboratories aren't able to mimic the shape of the cancer cell within the body, which can sometimes produce incorrect findings. The International Space Station's unique microgravity environment allows scientists to approach the research from a new, 3-D angle.

The Efficacy and Metabolism of Azonafide Antibody-Drug Conjugates (ADCs) in Microgravity investigation seeks to activate immunogenic cell death within the cancer cells, which should kill the cancer and prevent the disease from reoccurring in the future. The experiment explores a new drug and antibody combination that may increase the effectiveness of the treatment and decrease secondary side effects associated with chemotherapy.

"In space, you can grow larger and larger cancer tumors spherical in shape, so you have a better model of what's happening in the human body," said Luis Zea, research associate for Bioserve Space Technologies. "The chances of having false negatives or false positives is decreased."

Knowing how drug combinations work in microgravity is increasingly important as we plan for future deep-space missions, where we may need to be able to treat diseases such as cancer.

"We don't know if the cells will be metabolizing the drug at the same rate as they do on Earth," said Dhaval Shah, co-investigator. "In the long term, we need to be sure what drugs are going to work."

Once the Azonafide Antibody-Drug Conjugate (ADC) binds to the tumor surface, the construct is internalized by the tumor cells where the antibody is released and can begin cell death. Azonafide ADCs allow delivery of the drug to the tumor site, thereby avoiding the toxic side effects associated with chemotherapy. Credit: Oncolinx

To treat cancer currently, chemotherapy works by orally and intravenously injecting the patient with a drug to attack and kill cancer cells. Unfortunately, this untargeted approach also kills healthy cells.

The ADCs investigation is a combination of two molecules: a cancer-killing Azonafide drug and an antibody, which may enable a targeted approach for cancer treatment by only allowing the drug to kill cancer cells, while leaving the healthy cells intact.

"One of the reasons cancer cells grow in certain individuals is their defense mechanism fails to recognize them," said Shah. "This molecule also has the ability to wake up, or release the break, on existing immune cells within the cancer. In any given tumor, when these molecules are released [from the cancer cell], they 'wake up' the surrounding and stimulate the body's own immune system, making it recognize and kill the cells itself."

Cancer patients receiving chemotherapy often experience side effects such as nausea, fatigue, hair loss, cognitive impairment, and more during the course of treatment. Although this combination may decrease many of the negative side effects of chemotherapy, it may also have its own side effects, though potentially less severe and short-lived.

"The antibody is like a connector block," said Zea. "On one side it will only bind to the drug and the other side, may only bind to and not healthy . So by combining these two, the idea is to decrease the nasty side effects of ."

Explore further: Scientists develop new drug delivery method for cancer therapy

Related Stories

Scientists develop new drug delivery method for cancer therapy

March 16, 2017
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a new drug delivery method that produces strong results in treating cancers in animal models, including some hard-to-treat solid and ...

UIC conducts phase I drug study for advanced pancreatic cancer

June 3, 2014
Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

Antibody-drug compounds and immunotherapy to treat breast cancer

November 25, 2015
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University ...

Antibody drug conjugates may help personalize radiotherapy for patients with cancer

October 4, 2016
Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize ...

Screening drugs to kill cancer cells in their safe spaces

October 31, 2016
Existing chemotherapy approaches treat cancer by targeting cells that are actively multiplying and have a high metabolic rate. However, cancer stem cells can escape this targeting, leading to chemotherapy-resistant cancer ...

Localised immunotherapy new possibility to treat bladder cancer

December 8, 2016
Antibody-based immunotherapy is a new promising method to treat cancer. Unfortunately, today's treatments can result in adverse side effects. New findings from IGP show an alternative way to administer the therapy, which ...

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.